Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.